Valuation: Keros Therapeutics, Inc.

Market Cap 226M 199M 189M 170M 321M 21.67B 325M 2.26B 868M 11.08B 849M 830M 35.52B P/E 2026 *
-2.06x
P/E 2027 * -1.83x
Enterprise Value 226M 199M 189M 170M 321M 21.67B 325M 2.26B 868M 11.08B 849M 830M 35.52B EV / Sales 2026 *
14.5x
EV / Sales 2027 * 16.5x
Free-Float
46.49%
Yield 2026 *
-
Yield 2027 * -
1 day+1.88%
1 week-1.98%
1 month+2.89%
3 months+6.54%
6 months+3.26%
Current year-44.01%
1 week 10.92
Extreme 10.925
11.7
1 month 10.7
Extreme 10.7
12.05
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 2015-11-30
Director of Finance/CFO 55 2026-08-02
Chief Tech/Sci/R&D Officer 53 2019-05-31
Director TitleAgeSince
Chairman 70 2024-06-30
Director/Board Member 63 2016-03-31
Director/Board Member 50 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Sell

Executive/Senior Manager

-3,568 0.0180%
8/18/26 Sell

General Counsel

-4,485 0.0227%
8/18/26 Sell

Chief Financial Officer

-1,224 0.0062%
Change 5-day change 1-year change 3-year change Capi.($)
+1.88%-1.98%-27.94%-64.24% 222M
+4.16%-0.36%+49.37%+94.17% 71.53B
-0.19%+1.32%+37.20%+83.85% 60.12B
-1.51%+2.39%+9.10%+35.15% 48.85B
-0.05%+0.37%+41.54%+36.65% 44.28B
+0.38%+7.61%+339.53%+641.55% 43.83B
+0.18%+0.26%+7.41%+103.45% 41.53B
-0.67%+0.17%+7.60%+46.37% 30.13B
+4.77%+6.16%+36.77%+22.78% 27.98B
-1.29%-3.55%-20.74%+352.04% 25.25B
Average +0.77%+0.60%+47.99%+135.18% 39.37B
Weighted average by Cap. +0.80%+1.37%+60.88%+148.43%

Financials

2026 *2027 *
Net sales 15.57M 13.71M 12.99M 11.73M 22.1M 1.49B 22.39M 155M 59.8M 763M 58.45M 57.18M 2.45B 13.73M 12.09M 11.45M 10.34M 19.49M 1.32B 19.74M 137M 52.73M 673M 51.54M 50.42M 2.16B
Net income -110M -97.18M -92.08M -83.12M -157M -10.58B -159M -1.1B -424M -5.41B -414M -405M -17.34B -147M -130M -123M -111M -209M -14.13B -212M -1.47B -566M -7.23B -553M -541M -23.16B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
26-09-30 US$11.40 +1.88% 131,220
26-09-29 US$11.19 -0.80% 118,350
26-09-28 US$11.28 -2.93% 208,642
26-09-25 US$11.62 +0.61% 216,073
26-09-24 US$11.55 -0.69% 284,438
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.40USD
Average target price
19.83USD
Spread / Average Target
+73.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock